siRNA Drug Market Size, Analysis, and Forecast 2023–2030
Author : Ashwini Atole | Published On : 04 Jan 2024
siRNA drug market is a burgeoning segment within the vast pharmaceutical realm, currently estimated at USD 1475 billion in 2022 and projected to grow at a CAGR of 5% over the next six years.
This growth is fueled by the immense potential of siRNA technology to revolutionize targeted therapies for various diseases.
Unlike traditional chemical drugs, siRNAs offer a unique approach by silencing specific genes responsible for disease pathogenesis, providing a more precise and potentially curative treatment option.
To Know more about this report (Description, TOC and List of Tables and Figures) — siRNA Drug Market
Key Players:
The siRNA market landscape is still evolving, with a mix of established pharmaceutical giants and emerging biotech companies driving innovation. Some key players include:
- Genzyme
- Alnylam Pharmaceuticals
- Dicerna Pharmaceuticals
- Quark Pharmaceuticals
- Arrowhead Pharmaceuticals
- Exicure
- Miragen Therapeutics
- Silence Therapeutics
- Sylentis
- Avidity Biosciences
- BioNTech
- Moderna Therapeutics
- The WhiteOak Group, Inc.
Drivers and Opportunities:
Several factors are fueling the siRNA market growth:
- Rising burden of chronic diseases: The increasing prevalence of chronic diseases like cancer, rare genetic disorders, and neurodegenerative diseases is creating a demand for novel and effective treatment options, where siRNAs hold immense promise.
- Technological advancements: Continuous advancements in siRNA delivery systems, target identification, and manufacturing processes are addressing key challenges like off-target effects and short half-life, paving the way for improved siRNA therapeutics.
- Growing government and private investments: The potential of siRNA technology is attracting significant investments from governments and major pharmaceutical companies, further accelerating research and development efforts.
Segmentation by Type:
The siRNA market can be segmented based on the type of siRNA drug:
- Givlaari (givosiran): Approved for acute hepatic porphyria.
- Patisiran: Approved for hereditary transthyretin amyloidosis (hATTR).
- Lumasiran: Approved for primary hyperoxaluria type 1.
Segmentation by Application:
SiRNA drugs can be categorized based on their therapeutic applications:
- Single Gene Rare Diseases: siRNA therapies hold immense potential for treating rare genetic disorders caused by single gene mutations.
- Protein Deposition Diseases: SiRNAs can effectively target and silence genes responsible for protein aggregation in diseases like hATTR and Alzheimer’s disease.
- Chronic Liver Disease: SiRNAs are being explored for treating chronic liver diseases like hepatitis B and non-alcoholic steatohepatitis (NASH).
- Others: The potential applications of siRNA technology are vast and constantly expanding, with ongoing research into their use for cancer, cardiovascular diseases, and neurological disorders.
Segmentation by Region:
The siRNA market is geographically distributed as follows:
- North America: Holds the largest market share due to established pharmaceutical infrastructure and early adoption of innovative technologies.
- Europe: A significant market with a strong focus on rare disease research and development.
- Asia-Pacific: A rapidly growing market with increasing healthcare expenditure and focus on personalized medicine.
- Latin America and Middle East & Africa: Emerging markets with immense potential for future growth.
The siRNA drug market is poised for significant expansion, driven by the immense therapeutic potential of this technology and ongoing advancements in research and development.
Key players in the market are strategically positioned to capitalize on this growth by addressing challenges like delivery and cost, and expanding their pipelines into diverse therapeutic areas.
As siRNA technology matures and overcomes current limitations, it is expected to become a mainstream tool in the fight against various diseases, offering patients targeted and potentially curative treatment options.
